Literature DB >> 21753699

Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Akihiko Yoshida1, Koji Tsuta, Harumi Nakamura, Takashi Kohno, Fumiaki Takahashi, Hisao Asamura, Ikuo Sekine, Masashi Fukayama, Tatsuhiro Shibata, Koh Furuta, Hitoshi Tsuda.   

Abstract

A subset (1% to 5%) of non-small-cell lung carcinomas harbors the EML4-ALK fusion gene. Data from previous studies on the histomorphology of ALK-rearranged lung cancer are inconsistent, and the specific histologic parameters that characterize this subset and how accurately such parameters predict underlying ALK abnormality remain uncertain. To answer these questions, we performed a comprehensive histologic analysis of 54 surgically resected, extensively sampled ALK-rearranged lung carcinomas and compared them with 100 consecutive resections of ALK-wild-type lung cancers. All 54 cases showed at least a focal adenocarcinoma component, and 3 and 2 cases had additional squamous and sarcomatoid differentiation, respectively. Solid or acinar growth pattern, cribriform structure, presence of mucous cells (signet-ring cells or goblet cells), abundant extracellular mucus, lack of lepidic growth, and lack of significant nuclear pleomorphism were more common in ALK-positive cancers. Two recognizable constellations of findings, a solid signet-ring cell pattern and a mucinous cribriform pattern, were present at least focally in the majority (78%) of ALK-positive tumors, but were rare (1%) in ALK-negative tumors. Multivariate analysis showed that a combination of these 2 patterns was the most powerful histologic indicator of ALK rearrangement. Characteristic histologies were present both in primary sites and in metastases. Thus, histologic findings may help to identify cases for ALK testing. However, none of the histologic parameters were completely sensitive or specific to ALK rearrangement, and histomorphology should not replace confirmatory molecular or immunohistochemical studies. ALK-positive cancers commonly showed coexpression of thyroid transcription factor-1 and p63, and its significance is currently unclear.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753699     DOI: 10.1097/PAS.0b013e3182233e06

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  87 in total

1.  ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Authors:  Lynette M Sholl; Heather Sun; Mohit Butaney; Chengsheng Zhang; Charles Lee; Pasi A Jänne; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

Review 2.  Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.

Authors:  Hyojin Kim; Jin-Haeng Chung
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

4.  Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Authors:  Jing Zhao; Jianya Zhou; Zhen Chen; Bo Wang; Xiuming Zhang; Jianying Zhou; Wei Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

6.  ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

Authors:  Jamie E Chaft; Natasha Rekhtman; Marc Ladanyi; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

Review 7.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 8.  Current concepts on the molecular pathology of non-small cell lung carcinoma.

Authors:  Junya Fujimoto; Ignacio I Wistuba
Journal:  Semin Diagn Pathol       Date:  2014-06-12       Impact factor: 3.464

Review 9.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

Review 10.  The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Authors:  Jon Zugazagoitia; Ana Belen Enguita; Juan Antonio Nuñez; Lara Iglesias; Santiago Ponce
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.